Bio Farma is the only vaccine and sera manufacturer in Indonesia.

The embryonic form of this national pharmaceutical company has existed since the Dutch colonial rule. Established in August 6 !"#$ under the name of Parc Vaccinogen or Lands Koepok Inrichting subse%uently &no'n as the Pasteur Institute at that time the company occupied the area of (eltevreden army hospital in Batavia no' )a&arta. The company moved to Bandung in !#*+ occupying an area of #+ *$$ s%uare meters. Animal breeding for laboratory purposes 'as established at ,isarua-.embang on an area of *"* /!! s%uare meters. Follo'ing the nationali0ation of all former Dutch colonial companies series of changes have occurred 'ithin the company. In !#1" by virtue of the 2overnment 3egulation 4o *6 the company obtained the status as a public utility company 56erum7. By virtue of the 2overnment 3egulation 4o ! in !##1 it became a limited company &no'n as PT Bio Farma (Persero) located in Bandung (est )ava. Adopt World- lass Technolog! And "killed People 6lanning and Development Directorate is one of the vital components in Bio Farma8s production process. It8s in this division starts every initial planning for vaccine production research activities and cooperation 'ith third parties to improve production. At the global stage Bio Farma is one of do0ens of producers in the public sector 5government-o'ned7 'ith leading capability in vaccine technology. In only achieved through immeasurable supports given to Bio Farma by several vaccine institute and international donors such as Dutch8s 3i9& Institut voor :ol&ge0ondheid en ;ilieu <ygiene 53I:;7 )apan 6oliomyelitis 3esearch Institute 5)63I7 Bi&en Institute 5)apan7 Becton Dic&inson 5=>7 ?orea 2reen ,ross ,orporation 5?2,,7 3hein Biotech 52ermany7 ,ommunicable Disease ,ontrol 5,D,7 and 4ational Institute of <ealth 54I< - ;aryland =>7. Through these cooperation and assistance Bio Farma managed to conducts various programs to expand production including %uality control 'hich absolutely needs huge amount of funds larger than the company8s financing ability. Alongside 'ith the increasing vaccine production both to serve Indonesian government8s demand and =4 agencies such as =4I,EF activities in the %uality control unit also heighten including the %uality control for bacterial vaccines viral vaccines sera chemical physical and microbiological. To improve the @uality Assurance 'e have 'or&ed 'ith various international agencies such as )apan International ,ooperation Agency 5)I,A7 (<A and 3I:;.

Animal breeding is one of the main production supporting activity 'hich also gained serious attention. (e establish our o'n animal breeding facility to provide experimental animals to support production %uality control as 'ell as research and development. >ome of the experimental animals are ma%ua%es 5;acaca fascicularis used for production and in-process control of polio vaccines7 >6F chic&ens 5their eggs and embryos are used for production and in-process control of measles vaccines horses 5are used for production of anti-rabies serum antitetanus serum and anti-diphtheria serum7 sheep and goats5are used to prepare anti-serum7 rabbits 5are used for pyrogen test anti-serum test and anti-gen production7 guinea pigs 5are used for potency test detoxification test irreversibility test and safety test7 and 'hite mice 5are used for potency test safety test ;(2 test and .D B$ test7. Besides Bio Farma also engage in cooperation 'ith 3I:;-The 4etherland The 4ational Institute of :accine and Biological >ubstances 5I:A,7 - :ietnam and 6rimate 3esearch ,enter - Institut 6ertanian Bogor 5I6B-63,7. .aboratory of :irology 'hich 'as established in !#B has played important role in viral disease survey in Indonesia especially 6olio Dengue <anta and <epatitis B. (<A then assigned Bio Farma8 .aboratory of :irology as the .aboratory for 6olio Eradication. and has performed 'ell evidenced by its successfully proficiency test conducted by 3I:;- The 4etherland and international agency 'ith (<A-recognition. (ith various achievements of international level Bio Farma has been entrusted as one of (<A8s 2lobal Training 4et'or&. It8s understandable 'hen =4I,EF and (<A regularly sends trainee to get education and training at Bio Farma. They came among others from Bangladesh Bhutan ;yanmar 4epal 6hilippines >ri .an&a Thailand and :ietnam. Behind all those achievements are 6/+ highly dedicated ad s&illed 'or&ers. 3eali0ing the strength of the company relies on them Bio Farma regularly improve their s&ill through intensive training at home and overseas. Aur commitment to improve the manpo'er s&ill reflects in and ever-increasing budget for training

Vaccines
Product #ame omposition B,2 Indication Presentation ! Ampoule of *$ doses 5!$ ampoule per box7 ,ontainsC living For the organism of strain prevention of 5Bacillus ,almette tuberculosis 2uerin7 6aris

DT6

Each ml containsC 6urified diphtheria toxoid /$ .f and tetanus toxoid !B .f adsorbed to + mg aluminum phosphate */ million B. 6ertussis and $.! mg merthiolate as preservative

For simultaneous prevention of diphtheria tetanus and 'hooping cough

:ials of B ml 5!$ doses7. !$ vials per box

TT

Ane ml containsC For the *$ .f purified prevention of tetanus toxoid tetanus adsorbed to +$mg aluminum phosphate and $.! mg merthiolate as preservative Ane ml containsC purified diphtheria toxoid /$ .f and tetanus toxoid !B .f both adsorbed to + mg aluminum For simultaneous prevention of diphtheria and tetanus

:ials of B ml 5!$ doses7. !$ vials per box.

DT

- :ials of B ml 5!$ doses7. !$ :ials per box. - :ials of *B ml 5*$ doses7. !$ vials per box.

phosphate and $.! mg merthiolate as preservative

.ive Aral 6olio 5trivalent7

,ontains attenuated polio virus 5>abin7 type ! * and +. 6repared in primary &idney tissue culture

For the prevention of paralytic poliomyelitis

- :ials of ! ml 5!$ doses7. !$ vials per box. - :ials of * ml 5*$ doses7. !$ vials per box.

;easles 5,A;1$ strain7

.ive further For the attenuated vaccine prevention of 5,A; 1$ strain7. measles 6repared in chic&en embryo tissue culture

:ials of B ml 5!$ doses7. !$ vials per box.

<epatitis B 5D4A 3ecombinant7

For the prevention of <epatitis B

5 =ni9ect7

5 :ial7 >;B <uman 3abies :irus is inactivated 'ith Beta propiolacton. .yophyli0ed after reconstitution. Each ml containsC - !B.$ >;B suspension - $.! mg merthiolate - $.*B mg ?anamycin For the prevention of rabies 5hydrophobia7 in human Ane cure of >;B vaccine consist ofC - Box of 1 ampoules of >;B for subcutaneous administration

>erums Product #ame omposition Indication Presentation

Tetanus Anti >erum

6urified and concentrated plasma For the prevention and - Ampoule of ! of horses immuni0ed 'ith tetanus treatment of tetanus ml 5!B$$ I=7 toxoid. Each ! $$$ ml containsC - Ampoule of * - ! B$$ I= tetanus anti toxin for ml 5!$ $$$ I=7 prevention - :ial of / ml - B $$$ I= for treatment 5*$ $$$ I=7 5!$ vials per box7 6urified and concentrated plasma For simultaneous :ials of B ml 5!$ of horses immuni0ed 'ith prevention of doses7. !$ vials diphtheria toxoid. Each ! $$$ ml diphtheria tetanus and per box. contains * $$$ I= diphtheria anti 'hooping cough toxin >tabili0ed serum of purified For the prevention of :ials of *$ ml plasma from horses immuni0ed rabies in man bitten 'ith fixed rabies virus. Each ml by positive or suspect

Diphtheria Anti >erum

3abies Anti >erum

contains !$$ I=

rabid animals :ials of B ml 5!$ vials per box7

6olyvalent 6urified li%uid polyvalent For the treatment of >na&e :enom 5trivalent7 antivenom serum from persosns 'ho are Anti >erum horses previously immuni0ed bitten by poisonous 'ith sna&e venoms of 4aya sna&es Bungarus and An&ystrodon species